Prime Medicine has won an arbitration dispute against Beam Therapeutics, resolving a clash over gene-editing technology.[3181609] The arbitrator ruled that Prime's work on a gene-editing drug for the rare liver disease alpha-1 antitrypsin deficiency did not violate a 2019 agreement.[3181609][3179776] The outcome paves the way for Prime to start a clinical trial for AATD this quarter, lifting the biotech's stock by 11%.[3181609] However, the decision is a blow to Beam Therapeutics.[3181609]